The New England Journal of MedicineDaily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity

Orforglipron’s reported side effects were comparable to those of injectable GLP-1 receptor agonists.

New research reveals the potential of orforglipron, a nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist, to significantly reduce body weight in adults with obesity, making it a potential game changer in the battle against this global health concern.

Key Points:

• The Phase 2, double-blind trial involved 272 adults with obesity, or overweight with at least one weight-related coexisting condition, over 36 weeks.
• Participants were randomly assigned orforglipron doses of 12, 24, 36, or 45 mg, or a placebo, to be taken daily.
• Weight reduction of at least 10% by week 36 was achieved by 46 to 75% of participants on orforglipron compared to 9% on placebo.
• Mean body weight reduction ranged from -9.4% to -14.7% with orforglipron at week 36, as compared to -2.3% with placebo.
• The most common adverse events were gastrointestinal, mild to moderate, and resulted in 10 to 17% of participants discontinuing orforglipron use.

Additional Points:

• Adverse events reported with orforglipron were consistent with those experienced with injectable GLP-1 receptor agonists.
• The study reported improvements in all prespecified weight-related and cardiometabolic measures with orforglipron use.

Conclusion:

• The nonpeptide GLP-1 receptor agonist, orforglipron, demonstrated weight reduction efficacy in a clinical trial, with side effects similar to those of injectable GLP-1 receptor agonists.

Internal Medicine Latest Posts

• 26 Dietary Choices for Optimal Kidney HealthNovember 21, 2024
• 9 Health Benefits of CashewsNovember 21, 2024
• Off-brand Ozempic Leaves 10 Dead, 100 HospitalizedNovember 20, 2024
• Why Antidepressant Duloxetine Was RecalledNovember 20, 2024

Did You Know?
As of 2021, more than 650 million adults were obese worldwide, according to the World Health Organization.